
Opinion|Videos|December 14, 2023
Will Combination Therapies Replace Osimertinib Monotherapy as Standard-of-Care in Frontline EGFR-Mutant Advanced NSCLC?
Osimertinib monotherapy as the standard of treatment for frontline EGFR mutant advanced NSCLC will be replaced by combination therapies.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Afami-cel in Metastatic Synovial Sarcoma
2
The Moonlight Shift: Dr Joshua Richter on Myeloma, Myths, and the C-Word
3
Binimetinib Tablets Receive Tentative FDA Approval in Melanoma/NSCLC
4
How Are Key Lymphoma Data From ASCO and EHA 2026 Shaping Treatment?
5





















































































